Liposomal influenza vaccine

BioDrugs

Volumn 11, Issue 2, 1999, Pages 137-144

  Holm, Kristin J ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LIPOSOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE;

ANTIPHOSPHOLIPID SYNDROME; CELLULAR IMMUNITY; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INJECTION PAIN; PRIORITY JOURNAL; REVIEW; SEROCONVERSION;

EID: 0032988712     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199911020-00007     Document Type: Review

References (21)

1. Powers DC. Influenza virus vaccines. Drugs Today 1996 Apr-May; 32: 225-37
2. Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998 May 10; 47 RR-6: 1-26
3. Palache AM. Influenza vaccines: a reappraisal of their use. Drugs 1997 Dec; 54 (6): 841-56
4. Glathe H, Lange W. Influenza vaccination in older patients: immunogenicity, epidemiology and available agents. Drugs Aging 1995 May; 6: 368-87
5. Glück R. Liposomal presentation of antigens for human vaccines. In: Powell MF, Newman MJ, editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press, 1995: 325-45
6. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products: note for guidance on harmonisation of requirements for influenza vaccines. London, England, 1997
7. Glück R, Mischler R, Que JU, et al. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994 Jul 16; 344: 160-3
8. Conne P, Gauthey L, Vernet P. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997 Oct; 15 (15): 1675-9
9. Glück R et al. Virosomal Influenza Vaccine Versus Inflexal Berna 1990/91. Swiss Serum and Vaccine Institute Berne. KV9009; 1990 (Data on file)
10. De Bernardi di Valserra M. Comparison of Two Different Formulations of the Influenza Vaccine for the Season 1994/95 (Inflexal Berna® Whole-virus and Inflexal Berne Subunit IRIV. Swiss Serum and Vaccine Institute Berne. KV9414; 1995 (Data on file)
11. Al-Hamdan Y, Ledermann H-J. Inflexal V Influenza Vaccine: Clinical Trial to Assess the Immunogenicity of the 1997/98-season Virosomal Subunit Influenza Vaccine in Elderly and Young Individuals According to EMEA Regulations. Swiss Serum and Vaccine Institute Berne. KV9704; 1997 (Data on file)
12. Halabi A, Al-Hamdan Y. Clinical Trial to Assess the Immunogenicity of the 1998/99-season Virosomal Subunit Influenza Vaccine in Elderly and Young Individuals According to EMEA Regulations. Swiss Serum and Vaccine Institute Berne. KV9805; 1998 (Data on file)
13. Schaad UB, Buehlmann U, Burger R, et al. Comparison of immunogenicity and safety of a virosome and a subunit influenza vaccine in pediatric cystic fibrosis patients: A Swiss multicenter study [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
14. Schaad UB, Buehlmann U, Burger R, et al. Comparison of immunogenicity and safety of a virosome and a subunit influenza vaccine in pediatric cystic fibrosis patients: a Swiss multicenter study [poster]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
15. Angius E. Comparison of Two Different Formulations of Influenza Vaccine for the Season 1994/95 in Children (Inflexal Berna Subunit IRIV and Agrippal Biocine Subunit). Swiss Serum and Vaccine Institute Berne. KV9435; 1995 (Data on file)
16. Gauthey L, Conne P, Vernet P, et al. Yearly revaccination of elderly persons with a virosomal influenza vaccine in comparison to a subunit virus influenza vaccine. Swiss Serum and Vaccine Institute Berne. KV9426; 1994 (Data on file)
17. Saurwein-Teissl M, Zisterer K, Schmitt TL, et al. Whole virus influenza vaccine activates dendritic cells and stimulates cytokine production by peripheral blood mononuclear cells while subunit vaccines support T cell proliferation. Clin Exp Immunol 1998 Nov; 114: 271-6
18. Schaad UB, Bühlmann U, Burger R, et al. Randomized trial to compare the immunogenicity and safety of a virosomal and a subunit influenza vaccine in cystic fibrosis patients - Swiss multicenter study. Swiss Serum and Vaccine Institute Berne. KV9410; 1995 (Data on file)
19. Conne P, Gauthey L, Vernet P, et al. Virosomal Influenza Vaccine Versus Influvac 1993/94. Swiss Serum and Vaccine Institute Berne. KV9311; 1993 (Data on file)
20. Glück R, Mischler R, Finkel B, et al. Inflexal Berna 1992/93 Versus Virosomal Influenza Vaccine Versus Virosomal Tetanus Influenza Vaccine versus Influvac Duphar 1992/93. Swiss Serum and Vaccine Institute Berne. KV9225; 1993 (Data on file)
21. Cryz SJ, Que JU, Glück R. A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine 1996 Oct; 14 (14): 1381-3